Navidea Biopharmaceuticals announced that results from an investigator-initiated, comparative study of Lymphoseek (technetium Tc-99m tilmanocept) injection versus filtered Tc-99m Sulfur Colloid (fTcSC) were presented at the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. The study measured injection site pain in patients with breast cancer undergoing lymphoscintigraphy. Results of the randomized, double-blinded trial — led by Anne Wallace, M.D., professor of surgery at University of California, San Diego School of Medicine — highlighted that fTcSC caused statistically significant greater levels of pain after injection compared to Lymphoseek.

Piramal Imaging announced the presentation of additional analyses from its florbetaben phase 3 histopathology study, in which the florbetaben positron emission tomography (PET) signal from binding to morphologically distinct beta-amyloid plaques was examined. The analyses also examined the potential influence of plaques in the reference region for quantification. The results, which were presented at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Baltimore, provide additional details on the topographic distribution of different beta-amyloid aggregates in the brain and on quantification.

GE Healthcare announced that it has created a solution to make positron emission tomography (PET) tracers for diagnostic imaging more readily available. At the Society for Nuclear Medicine and Molecular Imaging (SNMMI), GE launched new products for radiopharmaceutical manufacturing, including GENtrace, a small cyclotron, with a smaller footprint that is optimized for ease-of-use; and FASTlab 2, a PET tracer production module with FDG Duo cassettes, to maximize the hot cell capacity.

Kromek announced the launch of eVance, a new generation of cadmium zinc telluride (CZT)-based SPECT (single photon emission computed tomography) cameras.

Steinberg Diagnostic Medical Imaging (SDMI) of Las Vegas has bolstered its capabilities by installing the United States’ first Celesteion PET/CT system from Toshiba America Medical Systems Inc. The Celesteion allows SDMI to provide the highest quality PET/CT (positron emission tomography/computed tomography) images and exams without sacrificing patient comfort.

The Center for Biomedical Research (CBR) is partnering with the Ackerman Cancer Center as part of a clinical meta-registry for clinical outcomes and long-term follow-up of cancer patients receiving proton therapy.

The Mevion S250 proton therapy system at Robert Wood Johnson University Hospital (RWJUH) is now treating patients, less than four weeks after the first Mevion patient was treated at Ackerman Cancer Center. The occasion marks the first time a proton manufacturer has simultaneously brought up two distinct facilities.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now